{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:36:33Z","timestamp":1785882993070,"version":"3.56.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01CA249279"],"award-info":[{"award-number":["R01CA249279"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01CA261995"],"award-info":[{"award-number":["R01CA261995"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01CA172382"],"award-info":[{"award-number":["R01CA172382"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01CA236780"],"award-info":[{"award-number":["R01CA236780"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH2010137"],"award-info":[{"award-number":["W81XWH2010137"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-22-1-0082"],"award-info":[{"award-number":["W81XWH-22-1-0082"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.xcrm.2024.101644","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T10:47:41Z","timestamp":1724150861000},"page":"101644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1281-3474","authenticated-orcid":false,"given":"Nima","family":"Sharifi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun A.","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason W.D.","family":"Hearn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Wozniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Zohren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sugg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel P.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnulf","family":"Stenzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101644_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev-med-051418-060357","article-title":"Sex hormones and prostate cancer","volume":"71","author":"Auchus","year":"2020","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.xcrm.2024.101644_bib2","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0021-9258(18)93542-8","article-title":"The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in\u00a0vivo and in\u00a0vitro","volume":"243","author":"Bruchovsky","year":"1968","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.xcrm.2024.101644_bib3","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/endrev\/bnab002","article-title":"Hormonal therapy for prostate cancer","volume":"42","author":"Desai","year":"2021","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.xcrm.2024.101644_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.105506","article-title":"The role of adrenal derived androgens in castration resistant prostate cancer","volume":"197","author":"Barnard","year":"2020","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.xcrm.2024.101644_bib5","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030452","article-title":"Androgen signaling in prostate cancer","volume":"7","author":"Dai","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.xcrm.2024.101644_bib6","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101644_bib7","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101644_bib8","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101644_bib9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101644_bib10","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101644_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.urology.2020.12.021","article-title":"Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group meeting summary","volume":"155","author":"Hofmann","year":"2021","journal-title":"Urology"},{"key":"10.1016\/j.xcrm.2024.101644_bib12","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1158\/0008-5472.CAN-21-4256","article-title":"Hypoxia-reoxygenation couples 3\u03b2HSD1 enzyme and cofactor upregulation to facilitate androgen biosynthesis and hormone therapy resistance in prostate cancer","volume":"82","author":"Qin","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101644_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/JCI161913","article-title":"Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation","volume":"133","author":"Cui","year":"2023","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2024.101644_bib14","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.cell.2013.07.029","article-title":"A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer","volume":"154","author":"Chang","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101644_bib15","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.tem.2020.05.006","article-title":"Through the looking-glass: reevaluating DHEA metabolism through HSD3B1 genetics","volume":"31","author":"Naelitz","year":"2020","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.xcrm.2024.101644_bib16","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1210\/en.2019-00366","article-title":"HSD3B1 genotypes conferring adrenal-restrictive and adrenal-permissive phenotypes in prostate cancer and\u00a0beyond","volume":"160","author":"Sabharwal","year":"2019","journal-title":"Endocrinology"},{"key":"10.1016\/j.xcrm.2024.101644_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.urology.2020.08.028","article-title":"Germline HSD3B1 genetics and prostate cancer outcomes","volume":"145","author":"Thomas","year":"2020","journal-title":"Urology"},{"key":"10.1016\/j.xcrm.2024.101644_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.6496","article-title":"HSD3B1 genotype and clinical outcomes in metastatic castration-sensitive prostate cancer","volume":"6","author":"Hearn","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2024.101644_bib19","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.annonc.2020.06.006","article-title":"HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies","volume":"31","author":"Khalaf","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2024.101644_bib20","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.annonc.2020.06.009","article-title":"Homozygous HSD3B1(1245C) inheritance and poor outcomes in metastatic castration-resistant prostate cancer with abiraterone or enzalutamide: what does it mean?","volume":"31","author":"Sharifi","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2024.101644_bib21","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.annonc.2020.04.473","article-title":"Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype","volume":"31","author":"Lu","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2024.101644_bib22","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S1470-2045(21)00402-2","article-title":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study","volume":"22","author":"Saad","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2024.101644_bib23","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2019.37.15_suppl.5008","article-title":"Alliance A031201: a phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ\/AAP) for metastatic castration resistant prostate cancer (mCRPC)","volume":"37","author":"Morris","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101644_bib24","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.150403","article-title":"Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer","volume":"6","author":"Kruse","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2024.101644_bib25","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101644_bib26","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00a0\u00d7\u00a02 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2024.101644_bib27","article-title":"Management of prostate cancer by targeting 3\u03b2HSD1 after enzalutamide and abiraterone treatment","volume":"3","author":"Mei","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2024.101644_bib28","article-title":"Inhibiting 3\u03b2HSD1 to eliminate the oncogenic effects of progesterone in prostate cancer","volume":"3","author":"Hou","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2024.101644_bib29","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163498","article-title":"BMX controls 3\u03b2HSD1 and sex steroid biosynthesis in cancer","volume":"133","author":"Li","year":"2023","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2024.101644_bib30","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1158\/0008-5472.CAN-17-3615","article-title":"BMX-mediated regulation of multiple tyrosine kinases contributes to castration resistance in prostate cancer","volume":"78","author":"Chen","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101644_bib31","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S1470-2045(16)30227-3","article-title":"HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study","volume":"17","author":"Hearn","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2024.101644_bib32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/bs.mie.2023.04.002","article-title":"Approaches to assessing 3\u03b2-hydroxysteroid dehydrogenase-1","volume":"689","author":"Alyamani","year":"2023","journal-title":"Methods Enzymol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124003586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124003586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T11:15:45Z","timestamp":1753182945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124003586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2666379124003586"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101644","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101644","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101644"}}